Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing
- PMID: 34517020
- DOI: 10.1016/j.mad.2021.111567
Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing
Abstract
NAD+ is a fundamental molecule in human life and health as it participates in energy metabolism, cell signalling, mitochondrial homeostasis, and in dictating cell survival or death. Emerging evidence from preclinical and human studies indicates an age-dependent reduction of cellular NAD+, possibly due to reduced synthesis and increased consumption. In preclinical models, NAD+ repletion extends healthspan and / or lifespan and mitigates several conditions, such as premature ageing diseases and neurodegenerative diseases. These findings suggest that NAD+ replenishment through NAD+ precursors has great potential as a therapeutic target for ageing and age-predisposed diseases, such as Alzheimer's disease. Here, we provide an updated review on the biological activity, safety, and possible side effects of NAD+ precursors in preclinical and clinical studies. Major NAD+ precursors focused on by this review are nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and the new discovered dihydronicotinamide riboside (NRH). In summary, NAD+ precursors have an exciting therapeutic potential for ageing, metabolic and neurodegenerative diseases.
Keywords: Ageing; Alzheimer’s disease; Healthspan; NAD(+).
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Similar articles
-
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.Cell Metab. 2018 Mar 6;27(3):513-528. doi: 10.1016/j.cmet.2017.11.002. Epub 2017 Dec 14. Cell Metab. 2018. PMID: 29249689 Free PMC article. Review.
-
Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach.J Alzheimers Dis. 2024;101(s1):S467-S477. doi: 10.3233/JAD-231277. J Alzheimers Dis. 2024. PMID: 39422945 Review.
-
Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells.Mol Metab. 2017 May 29;6(8):819-832. doi: 10.1016/j.molmet.2017.05.011. eCollection 2017 Aug. Mol Metab. 2017. PMID: 28752046 Free PMC article.
-
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.Exp Gerontol. 2020 Apr;132:110831. doi: 10.1016/j.exger.2020.110831. Epub 2020 Jan 7. Exp Gerontol. 2020. PMID: 31917996
-
NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells.Nat Commun. 2016 Oct 11;7:13103. doi: 10.1038/ncomms13103. Nat Commun. 2016. PMID: 27725675 Free PMC article.
Cited by
-
Safety Evaluation for Restorin® NMN, a NAD+ Precursor.Front Pharmacol. 2021 Nov 11;12:749727. doi: 10.3389/fphar.2021.749727. eCollection 2021. Front Pharmacol. 2021. PMID: 34867355 Free PMC article.
-
NAD+ Precursors and Intestinal Inflammation: Therapeutic Insights Involving Gut Microbiota.Nutrients. 2023 Jun 30;15(13):2992. doi: 10.3390/nu15132992. Nutrients. 2023. PMID: 37447318 Free PMC article. Review.
-
Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias.Alzheimers Dement. 2023 Mar;19(3):1041-1066. doi: 10.1002/alz.12845. Epub 2022 Dec 8. Alzheimers Dement. 2023. PMID: 36479795 Free PMC article. Review.
-
Roles of NAD+ in Acute and Chronic Kidney Diseases.Int J Mol Sci. 2022 Dec 21;24(1):137. doi: 10.3390/ijms24010137. Int J Mol Sci. 2022. PMID: 36613582 Free PMC article. Review.
-
Accelerated neuronal aging in vitro ∼melting watch ∼.Front Aging Neurosci. 2022 Aug 9;14:868770. doi: 10.3389/fnagi.2022.868770. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36016855 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
